Home LiteratureArticle Details
PMID: 19240792 Published · ppublish English Evaluation Study Journal Article Research Support, Non-U.S. Gov't

Mutation detection by real-time PCR: a simple, robust and highly selective method.

PloS one ·Vol. 4 ·No. 2 ·2009-00-00 ·Pages e4584

Morlan J, Baker J, Sinicropi D

Abstract

Molecular tests for diagnosis of disease, particularly cancer, are gaining increased acceptance by physicians and their patients for disease prognosis and selection of treatment options. Gene expression profiles and genetic mutations are key parameters used for the molecular characterization of tumors. A variety of methods exist for mutation analysis but the development of assays with high selectivity tends to require a process of trial and error, and few are compatible with real-time PCR. We sought to develop a real-time PCR-based mutation assay methodology that successfully addresses these issues. The method we describe is based on the widely used TaqMan real-time PCR technology, and combines Allele-Specific PCR with a Blocking reagent (ASB-PCR) to suppress amplification of the wildype allele. ASB-PCR can be used for detection of germ line or somatic mutations in either DNA or RNA extracted from any type of tissue, including formalin-fixed paraffin-embedded tumor specimens. A set of reagent design rules was developed enabling sensitive and selective detection of single point substitutions, insertions, or deletions against a background of wild-type allele in thousand-fold or greater excess. ASB-PCR is a simple and robust method for assaying single nucleotide mutations and polymorphisms within the widely used TaqMan protocol for real time RT-PCR. The ASB-PCR design rules consistently produce highly selective mutation assays while obviating the need for redesign and optimization of the assay reagents. The method is compatible with formalin-fixed tissue and simultaneous analysis of gene expression by RT-PCR on the same plate. No proprietary reagents other than those for TaqMan chemistry are required, so the method can be performed in any research laboratory with real-time PCR capability.

MeSH Terms
Clinical Laboratory Techniques DNA Mutational Analysis/methods,standards Humans Methods Mutation Polymerase Chain Reaction/methods,standards Polymorphism, Single Nucleotide Reagent Kits, Diagnostic
Chemicals
Reagent Kits, Diagnostic
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Morlan John
Genomic Health, Inc., Redwood City, California, United States of America.
Baker Joffre
Sinicropi Dominick
References (42)
42 references, click to expand
  1. Real-time genotyping with oligonucleotide probes containing locked nucleic acids.
    Anal Biochem. 2004 Jan 1;324(1):143-52 PMID: 14654057
  2. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
    J Clin Oncol. 2008 Apr 1;26(10):1626-34 PMID: 18316791
  3. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
    Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 PMID: 15329413
  4. Allelic variation in human gene expression.
    Science. 2002 Aug 16;297(5584):1143 PMID: 12183620
  5. Allelic variation in gene expression is common in the human genome.
    Genome Res. 2003 Aug;13(8):1855-62 PMID: 12902379
  6. Emerging molecular markers of cancer.
    Nat Rev Cancer. 2002 Mar;2(3):210-9 PMID: 11990857
  7. A high frequency of sequence alterations is due to formalin fixation of archival specimens.
    Am J Pathol. 1999 Nov;155(5):1467-71 PMID: 10550302
  8. Low copy number DNA template can render polymerase chain reaction error prone in a sequence-dependent manner.
    J Mol Diagn. 2005 Feb;7(1):36-9 PMID: 15681472
  9. A novel blocker-PCR method for detection of rare mutant alleles in the presence of an excess amount of normal DNA.
    Nucleic Acids Res. 1992 May 25;20(10):2493-6 PMID: 1598207
  10. Determining SNP allele frequencies in DNA pools.
    Biotechniques. 2000 Mar;28(3):464-6, 468, 470 PMID: 10723558
  11. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
    N Engl J Med. 2004 Dec 30;351(27):2817-26 PMID: 15591335
  12. Detection and quantification of mutations in the plasma of patients with colorectal tumors.
    Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16368-73 PMID: 16258065
  13. PAP: detection of ultra rare mutations depends on P* oligonucleotides: "sleeping beauties" awakened by the kiss of pyrophosphorolysis.
    Hum Mutat. 2004 May;23(5):426-36 PMID: 15108273
  14. Enhanced allele-specific PCR discrimination in SNP genotyping using 3' locked nucleic acid (LNA) primers.
    Hum Mutat. 2003 Jul;22(1):79-85 PMID: 12815597
  15. Genotyping with TaqMAMA.
    Genomics. 2004 Feb;83(2):311-20 PMID: 14706460
  16. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
    J Clin Oncol. 2005 Sep 1;23(25):5900-9 PMID: 16043828
  17. Dissociation kinetics of 19 base paired oligonucleotide-DNA duplexes containing different single mismatched base pairs.
    Nucleic Acids Res. 1987 Jan 26;15(2):797-811 PMID: 3822815
  18. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
    J Clin Oncol. 2006 Aug 10;24(23):3726-34 PMID: 16720680
  19. Allele-specific competitive blocker PCR: a one-step method with applicability to pool screening.
    Hum Mutat. 1995;6(2):163-9 PMID: 7581400
  20. High-throughput SNP allele-frequency determination in pooled DNA samples by kinetic PCR.
    Genome Res. 2000 Feb;10(2):258-66 PMID: 10673283
  21. Allele-specific competitive blocker-PCR detection of rare base substitution.
    Methods Mol Biol. 2005;291:235-45 PMID: 15502227
  22. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.
    Cancer Res. 2006 Apr 15;66(8):3992-5 PMID: 16618717
  23. Cancer genes and the pathways they control.
    Nat Med. 2004 Aug;10(8):789-99 PMID: 15286780
  24. Extension of base mispairs by Taq DNA polymerase: implications for single nucleotide discrimination in PCR.
    Nucleic Acids Res. 1992 Sep 11;20(17):4567-73 PMID: 1408758
  25. FLAG assay as a novel method for real-time signal generation during PCR: application to detection and genotyping of KRAS codon 12 mutations.
    Nucleic Acids Res. 2007;35(19):e131 PMID: 17932053
  26. ARMS allele-specific amplification-based detection of mutant p53 DNA and mRNA in tumors of the breast.
    Clin Chem. 2001 Apr;47(4):774-8 PMID: 11274040
  27. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.
    J Natl Cancer Inst. 1998 May 6;90(9):675-84 PMID: 9586664
  28. Quantitation of target molecules from polymerase chain reaction-based limiting dilution assays.
    AIDS Res Hum Retroviruses. 1997 Jun 10;13(9):737-42 PMID: 9171217
  29. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
    Science. 2004 Jun 4;304(5676):1497-500 PMID: 15118125
  30. Allele-specific enzymatic amplification of beta-globin genomic DNA for diagnosis of sickle cell anemia.
    Proc Natl Acad Sci U S A. 1989 Apr;86(8):2757-60 PMID: 2704745
  31. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay.
    Am J Pathol. 2004 Jan;164(1):35-42 PMID: 14695316
  32. Diagnostic biochip array for fast and sensitive detection of K-ras mutations in stool.
    Clin Chem. 2002 Mar;48(3):428-35 PMID: 11861435
  33. Genetic instabilities in human cancers.
    Nature. 1998 Dec 17;396(6712):643-9 PMID: 9872311
  34. Peptide nucleic acid clamp PCR: a novel K-ras mutation detection assay for colorectal cancer micrometastases in lymph nodes.
    Int J Cancer. 2004 Sep 1;111(3):409-14 PMID: 15221969
  35. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS).
    Nucleic Acids Res. 1989 Apr 11;17(7):2503-16 PMID: 2785681
  36. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study.
    Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1193-7 PMID: 11097226
  37. Differential allelic expression in the human genome: a robust approach to identify genetic and epigenetic cis-acting mechanisms regulating gene expression.
    PLoS Genet. 2008 Feb 29;4(2):e1000006 PMID: 18454203
  38. Assessing EGFR mutations.
    N Engl J Med. 2006 Feb 2;354(5):526-8; author reply 526-8 PMID: 16452569
  39. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.
    J Clin Oncol. 2008 Jan 20;26(3):374-9 PMID: 18202412
  40. Effects of primer-template mismatches on the polymerase chain reaction: human immunodeficiency virus type 1 model studies.
    Nucleic Acids Res. 1990 Feb 25;18(4):999-1005 PMID: 2179874
  41. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
    PLoS Med. 2005 Mar;2(3):e73 PMID: 15737014
  42. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
    N Engl J Med. 2004 May 20;350(21):2129-39 PMID: 15118073
Article Info
Journal
PloS one
Abbr.
PLoS One
ISSN
1932-6203
Published
2009-00-00
Epub
2009-00-25
Pages
e4584
Language
English
Region
United States
NLM ID
101285081
PMCID
PMC2642996
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]